Array BioPharma Inc. believes its latest deal could be the last time it
out-licenses worldwide rights to assets created by its small molecule discovery
and design platform. Last week's deal with Novartis AG, plus a
collaboration late last year with Amgen Inc., gave Array co-promotion
rights in the U.S., providing the potential to get a sales force on the ground
to commercialize its own products.
Array, which has been building
its bioinformatics-driven discovery platform since 1998, has 16 compounds in
development through partners. But it has nine unpartnered programs, four of
which are in the clinic.